TSE:PSYG Stock Latest News

Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

PremiumPress Releases

1M ago

Psyence Group’s Associate Advances Psilocybin Trial

PremiumCompany Announcements

5M ago

Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

PremiumPress Releases

5M ago

Psyence Group Finalizes Non-Clinical Business Overhaul

PremiumCompany Announcements

5M ago

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

PremiumPress ReleasesPsyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

5M ago

Psyence Biomedical Advances Psilocybin Palliative Care Study

Company Announcements

Psyence Biomedical Advances Psilocybin Palliative Care Study

6M ago

Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

Press Releases

Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

6M ago

Psyence Group Announces Successful Division Spin-Out

PremiumCompany Announcements

6M ago

Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp

PremiumPress Releases

7M ago

Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp

PremiumPress Releases

7M ago

Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination

PremiumPress Releases

8M ago

PremiumPress ReleasesPsyence Group Announces Resignation of Board Member

10M ago

Psyence Group Announces SEC Effectiveness of F-4 for Proposed Business Combination Between Subsidiary and Nasdaq Listed Newcourt Acquisition Corp

Press Releases

Psyence Group Announces SEC Effectiveness of F-4 for Proposed Business Combination Between Subsidiary and Nasdaq Listed Newcourt Acquisition Corp

10M ago

Press Releases

Psyence Production Expands Capability

10M ago

Psyence Group Announces Closing of Private Placement & Conclusion of Loan Agreement

PremiumPress Releases

1y ago

Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement

PremiumPress Releases

1y ago

Psyence Group Corporate Update

PremiumPress Releases

1y ago

Psyence Appoints Intellectual Property Expert to Its Board of Directors

PremiumPress Releases

1y ago

PremiumPress ReleasesPsyence Group Announces Closing of Fourth Tranche of Private Placement and Conversion of Convertible Debt Note

1y ago

Psyence Group Announces Cantheon Capital Private Placement

Press Releases

Psyence Group Announces Cantheon Capital Private Placement

1y ago

Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia

Press Releases

Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia

1y ago